scholarly journals β-blocker therapy and heart rate control during exercise testing in the general population: role of a common G-protein β-3 subunit variant

2010 ◽  
Vol 11 (9) ◽  
pp. 1209-1221 ◽  
Author(s):  
Marcus Dörr ◽  
Carsten O Schmidt ◽  
Thomas Spielhagen ◽  
Alexa Bornhorst ◽  
Katharina Hentschel ◽  
...  
Keyword(s):  
Heart Rate ◽  
General Population ◽  
G Protein ◽  
Exercise Testing ◽  
Rate Control ◽  
Heart Rate Control ◽  
Blocker Therapy ◽  
Β Blocker

Perioperative β-blocker therapy and heart rate control during noncardiac surgery

2007 ◽  
Vol 194 (2) ◽  
pp. 189-191 ◽  
Author(s):  
Carolyn Berg ◽  
David H. Berger ◽  
Ayuk Makia ◽  
Caleb Whalen ◽  
Daniel Albo ◽  
...  
Keyword(s):  
Heart Rate ◽  
Rate Control ◽  
Noncardiac Surgery ◽  
Heart Rate Control ◽  
Blocker Therapy ◽  
Β Blocker

P3517Failure to achieve adequate heart rate control in women during therapy optimization

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
V Kutyifa ◽  
J W Erath ◽  
A Burch ◽  
B Assmus ◽  
D Bondermann ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Rate ◽  
Beta Blocker ◽  
Rate Control ◽  
Beta Blockers ◽  
Heart Rate Control ◽  
Blocker Therapy ◽  
Cardioverter Defibrillator ◽  
Beta Blocker Therapy ◽  
The Mean

Abstract Background Previous studies highlighted the importance of adequate heart rate control in heart failure patients, and suggested under-treatment with beta-blockers especially in women. However, data on women achieving effective heart rate control during beta-blocker therapy optimization are lacking. Methods The wearable cardioverter defibrillator (WCD) allows continuous monitoring of heart rate (HR) trends during WCD use. In the current study, we assessed resting HR trends (nighttime: midnight-7am) in women, both at the beginning of WCD use and at the end of WCD use to assess the adequacy of beta-blockade following a typical 3 months of therapy optimization with beta-blockers. An adequate heart rate control was defined as having a nighttime HR <70 bpm at the end of the 3 months. Results There were a total of 21,453 women with at least 30 days of WCD use (>140 hours WCD use on the first and last week). The mean age was 67 years (IQR 58–75). The mean nighttime heart rate was 72 bpm (IQR 65–81) at the beginning of WCD use, that decreased to 68 bpm (IQR 61–76) at the end of WCD use with therapy optimization. Women had an insufficient heart rate control with resting heart rate ≥70 bpm in 59% at the beginning of WCD use that decreased to 44% at the end of WCD use, but still remained surprisingly high. Interestingly, there were 21% of the women starting with HR ≥70 bpm at the beginning of use (BOU) who achieved adequate heart rate control by the end of use (EOU). Interestingly, 6% of women with adequate heart rate control at the start of therapy optimization ended up having higher heart rates >70 bpm at the end of the therapy optimization time period (Figure). Figure 1 Conclusions A significant proportion of women with heart failure and low ejection fraction do not reach an adequate heart rate control during the time of beta blocker initiation/titration. The wearble cardioverter defibrillator is a monitoring device that has been demonstrated in this study to appropriately identify patients with inadequate heart rate control at the end of the therapy optimization period. The WCD could be utilized to improve management of beta-blocker therapy in women and improve the achievement of adequate heart rate control in women.

scholarly journals PROGNOSTIC ROLE OF ATRIAL FIBRILLATION AND HEART RATE CONTROL IN CHRONIC HEART FAILURE PATIENTS

2013 ◽  
Vol 61 (10) ◽  
pp. E735
Author(s):  
Savina Nodari ◽  
Marco Triggiani ◽  
Laura Lupi ◽  
Alessandra Manerba ◽  
Giuseppe Milesi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
Heart Rate ◽  
Chronic Heart Failure ◽  
Rate Control ◽  
Heart Rate Control ◽  
Prognostic Role ◽  
Heart Failure Patients

Impaired parasympathetic heart rate control in mice with a reduction of functional G protein βγ-subunits

2002 ◽  
Vol 282 (2) ◽  
pp. H445-H456 ◽  
Author(s):  
Josef Gehrmann ◽  
Michael Meister ◽  
Colin T. Maguire ◽  
Donna C. Martins ◽  
Peter E. Hammer ◽  
...  
Keyword(s):  
Heart Rate ◽  
Heart Rate Variability ◽  
Transgenic Mice ◽  
G Protein ◽  
Rate Control ◽  
Sinus Node ◽  
Physiological Role ◽  
Heart Rate Control ◽  
Electrophysiological Studies

Acetylcholine released on parasympathetic stimulation slows heart rate through activation of muscarinic receptors on the sinus nodal cells and subsequent opening of the atrial muscarinic potassium channel (KACh). KACh is directly activated by G protein βγ-subunits. To elucidate the physiological role of Gβγ for the regulation of heart rate and electrophysiological function in vivo, we created transgenic mice with a reduced amount of membrane-bound Gβ protein by overexpressing nonprenylated Gγ2-subunits in their hearts using the α-myosin heavy chain promoter. At baseline and after muscarinic stimulation with carbachol, heart rate and heart rate variability were determined with electrocardiogram telemetry in conscious mice and in vivo intracardiac electrophysiological studies in anesthetized mice. Reduction of the amount of functional Gβγ protein by >50% caused a pronounced blunting of the carbachol-induced bradycardia as well as the increases in time- and frequency-domain indexes of heart rate variability and baroreflex sensitivity that were observed in wild types. In addition, sinus node recovery time and inducibility of atrial arrhythmias were reduced in transgenic mice. Our data demonstrate in vivo that Gβγ plays a crucial role for parasympathetic heart rate control, sinus node automaticity, and atrial arrhythmia vulnerability.

Heart Rate Control in Patients With Atrial Fibrillation Referred for Exercise Testing

2008 ◽  
Vol 102 (6) ◽  
pp. 704-708 ◽  
Author(s):  
Anthony A. Hilliard ◽  
Todd D. Miller ◽  
David O. Hodge ◽  
Raymond J. Gibbons
Keyword(s):  
Atrial Fibrillation ◽  
Heart Rate ◽  
Exercise Testing ◽  
Rate Control ◽  
Heart Rate Control
Sign in / Sign up

Export Citation Format

Share Document